A case of aortic dissection with highly suggestive features of COVID-19.

INTRODUCTION: Aortic dissection is a cardiovascular emergency with an overall in-hospital mortality rate of 27.4%, and with every hour without intervention, the mortality rate increases by 1%-2% in the first 48 hours. Thoracic aortic dissection typically presents with tearing chest, back, or abdominal pain. Coronavirus disease 2019 (COVID-19) is a viral disease caused by severe acute respiratory syndrome-coronavirus 2 (SARS-Cov2), which has been declared a pandemic by the World Health Organization (WHO) and usually manifests with respiratory symptoms, including cough, shortness of breath, flu-like symptoms, and fever. This case report highlights an important impact of the COVID-19 pandemic on the identification and management of aortic dissection in the emergency department. CASE REPORT: A 35-year-old Bahraini male, a suspected case of Marfan syndrome, presented with complaints of shortness of breath and worsening productive cough after returning from the United States (U.S). He denied any chest, back, or abdominal pain, dizziness, weakness in any limb, gait disturbance, headache, or change in vision. He was considered high risk for COVID-19 because of the recent travel and respiratory symptoms and was diagnosed incidentally with ascending aortic dissection along with a right lung consolidation. His SARS-Cov2 PCR came negative thrice during hospital stay, and he underwent elective cardiothoracic surgery. CONCLUSION: The COVID-19 pandemic has been a major stressor for the healthcare system worldwide, inflicting serious threats. Aortic dissection is one of the major life-threatening diseases that needs to be identified early on in the emergency department; however, in this case delayed diagnosis raised significant concerns due to underlying evolving triaging system for COVID-19 and atypical and overlapping clinical presentation. Further research is needed to look for COVID-19-associated factors, affecting the standard of care in the emergency department. Improving handover can directly impact patient care; therefore, it should be optimized.

Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.

BACKGROUND: Hydroxychloroquine (HC) ± azithromycin (AZ) is widely used for Covid-19. The Qatar Prospective RCT of Expediting Coronavirus Tapering (Q-PROTECT) aimed to assess virologic cure rates of HC±AZ in cases of low-acuity Covid-19. METHODS: Q-PROTECT employed a prospective, placebo-controlled design with blinded randomization to three parallel arms: placebo, oral HC (600 mg daily for one week), or oral HC plus oral AZ (500 mg day one, 250 mg daily on days two through five). At enrollment, non-hospitalized participants had mild or no symptoms and were within a day of Covid-19 positivity by polymerase chain reaction (PCR). After six days, intent-to-treat (ITT) analysis of the primary endpoint of virologic cure was assessed using binomial exact 95% confidence intervals (CIs) and χ2 testing. (ClinicalTrials.gov NCT04349592, trial status closed to new participants.). FINDINGS: The study enrolled 456 participants (152 in each of three groups: HC+AZ, HC, placebo) between 13 April and 1 August 2020. HC+AZ, HC, and placebo groups had 6 (3·9%), 7 (4·6%), and 9 (5·9%) participants go off study medications before completing the medication course (p = 0·716). Day six PCR results were available for all 152 HC+AZ participants, 149/152 (98·0%) HC participants, and 147/152 (96·7%) placebo participants. Day six ITT analysis found no difference (p = 0·821) in groups' proportions achieving virologic cure: HC+AZ 16/152 (10·5%), HC 19/149 (12·8%), placebo 18/147 (12·2%). Day 14 assessment also showed no association (p = 0·072) between study group and viral cure: HC+AZ 30/149 (20·1%,), HC 42/146 (28·8%), placebo 45/143 (31·5%). There were no serious adverse events. INTERPRETATION: HC±AZ does not facilitate virologic cure in patients with mild or asymptomatic Covid-19. FUNDING: The study was supported by internal institutional funds of the Hamad Medical Corporation (government health service of the State of Qatar).

Improving influenza vaccination rates of healthcare workers: a multipronged approach in Qatar.

We assessed whether an influenza vaccination (IV) campaign was effective at increasing vaccination rate in healthcare workers (HCWs) in 2 hospitals in Doha, Qatar that had no mandatory IV policy. The campaign comprised promotional, educational and vaccine delivery interventions; a dedicated IV team; telephone hotline; free IV with improved access, leadership involvement; incentives; group educational sessions; and reporting/tracking activities. During the 2014/15 influenza season, IV rates according to hospital and HCW category were calculated and compared with the 2 seasons before the intervention. The combined mean rate for IV for both hospitals increased for 2014/15 (64.3%) compared with 2013/14 (37.2%) and 2012/13 (28.4%). There was increased IV uptake among doctors and nurses at each hospital, and the IV rate for the 2 hospitals (59.1 and 69.5%) were higher than in 2013/14 (21.1% and 53.2%) and 2012/13 (17.2% and 39.6%). The findings highlight the importance of improving IV rates among HCWs in hospitals with no mandatory vaccination policies through multicomponent interventions.

Improving influenza vaccination rates of healthcare workers: a multipronged approach in Qatar

We assessed whether an influenza vaccination [IV] campaign was effective at increasing vaccination rate in healthcare workers [HCWs] in 2 hospitals in Doha, Qatar that had no mandatory IV policy. The campaign comprised promotional, educational and vaccine delivery interventions; a dedicated IV team; telephone hotline; free IV with improved access, leadership involvement; incentives; group educational sessions; and reporting/tracking activities. During the 2014/15 influenza season, IV rates according to hospital and HCW category were calculated and compared with the 2 seasons before the intervention. The combined mean rate for IV for both hospitals increased for 2014/15 [64.3%] compared with 2013/14 [37.2%] and 2012/13 [28.4%]. There was increased IV uptake among doctors and nurses at each hospital, and the IV rate for the 2 hospitals [59.1 and 69.5%] were higher than in 2013/14 [21.1% and 53.2%] and 2012/13 [17.2% and 39.6%]. The findings highlight the importance of improving IV rates among HCWs in hospitals with no mandatory vaccination policies through multicomponent interventions

Nous avons cherché à déterminer si la réalisation d'une campagne de vaccination antigrippale influait sur l'augmentation du taux de vaccination chez les agents de santé de deux hôpitaux de Doha [Qatar], qui ne disposaient pas de politiques de vaccination antigrippale obligatoire. La campagne comprenait les éléments suivants: des prestations de promotion et d'éducation, et des interventions concernant les services de vaccination; des équipes de vaccination antigrippale dédiées; une ligne téléphonique spéciale; la vaccination antigrippale gratuite avec un accès amélioré; l'implication de la direction; des mesures incitatives; des sessions de groupe éducatives; et des activités de notification/de suivi. Pendant la saison grippale 2014-2015, les taux de vaccination antigrippale pour les hôpitaux et pour chaque catégorie d'agents de santé ont été calculés et comparés avec les deux saisons précédant l'intervention. Le taux moyen combiné pour la vaccination antigrippale pour les deux hôpitaux avait augmenté sur la période 2014-2015 [64,3%] par rapport aux périodes 2013-2014 [37,2%] et 2012-2013 [28,4%]. Le recours à la vaccination était en augmentation parmi les médecins et les personnels infirmiers dans chaque hôpital, et le taux de vaccination antigrippale pour les deux hôpitaux [59,1% et 69,5%] était plus élevé qu'en 2013-2014 [21,1% et 53,2%] et qu'en 2012-2013 [17,2% et 39,6%]. Les résultats soulignent l'importance d'améliorer, au moyen d'interventions à multiples composantes, les taux de vaccination antigrippale parmi les agents de santé dans les hôpitaux où il n'existe pas de politiques de vaccination obligatoire